tbuckley/cabot-search huggingface dataset:
Combination chemotherapy of acute leukemia and Hodgkin's disease
Authors: E. Frei
Journal: JAMA (1972)

The best single agent for the treatment of acute leukemia in adults is cytarabine hydrochloride. Intermittent treatment with this agent is superior to daily treatment in experimental systems. A quantitative study was performed in 136 adults with acute leukemia wherein patients were randomly allocated to two treatments: (1) five-day courses of intravenous administration at 150 mg/sq m/day every two to three weeks, and (2) two-day courses of intravenous administration at a dose of 400 mg/sq m/day every two weeks. The five-day course resulted in a 38% complete remission rate which was significantly superior to the two-day course. In pilot studies, the tolerated doses of five days of cytarabine hydrochloride in combination with cyclophosphamide and subsequently with cyclophosphamide, vincristine, and prednisone (the COAP program) were established. Following this, a quantitative study was performed in 121 patients comparing five-day courses of cytarabine hydrochloride with five-day courses of COAP. Courses were given every
Departure
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
How coronary angiography is used. Clinical determinants of appropriateness
Authors: M. R. Chassin
Journal: JAMA (1987)

Using ratings of appropriateness derived from an expert physician panel, we measured how appropriately physicians in 1981 performed coronary angiography in a randomly selected, community-based sample of cases in the Medicare population. We studied large geographic areas (three sites) in three states, representing regions of high and low use. The high-use site had fewer procedures classified as appropriate (72%) than either low-use site (77% and 81%, respectively). Over all sites, 17% of procedures were classified as inappropriate. Patients in the high-use site were older, had less severe angina, and were less intensively medically treated than patients in either of the low-use sites. Patients without angina who had not undergone exercise testing constituted the most common subgroup of inappropriate cases. Although overall differences in appropriateness were not large, practice differences do exist. This analysis of practice differences among study sites provides the clinical basis for understanding the small, but significant, differences in the appropriateness of use of coronary angiography. The finding of 17% inappropriate use may be cause for concern. (<i>JAMA</i>1987;258:2543-2547)
Highlights
Journal: JAMA Dermatology (2018)

Trends in Liability Claims Against Dermatologists 160Dermatologists are sued less frequently than those in other specialties, but about 36% will be sued at least once by age 45 years.Recognizing malpractice trends is important for establishing safeguards for patient care and minimizing liability.In this analysis of malpractice data from a national registry, Kornmehl et al demonstrate that dyschromia was the most common adverse outcome alleged in lawsuits.Clinicians may not associate dyschromia with substantial morbidity, and clinician and patient perceptions of adverse outcomes may differ.Improving clinical and communication skills may help reduce dermatologists' liability.Konda and Torres provide an Editorial.
In Brief
Authors: Alan T. Marty
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Morton Lecture on Cancer and Cancerous Diseases
Authors: S. Wells
Journal: BMJ (1888)

<h3>Background</h3> Germline pathogenic variants in <i>DICER1</i> cause DICER1 syndrome, an autosomal dominant, pleiotropic tumour predisposition syndrome with variable expressivity and reduced penetrance for specific dysplastic and neoplastic lesions. Recently, a syndrome with the acronym GLOW (<i>G</i>lobal developmental delay, <i>L</i>ung cysts, <i>O</i>vergrowth, <i>W</i>ilms tumour) was described in two children with mosaic missense mutations in hotspot residues of the DICER1 RNase IIIb domain. <h3>Methods</h3> Whole genome sequencing, exome sequencing, Sanger sequencing, digital PCR and a review of Wilms tumours with <i>DICER1</i> RNase III domain mutations were performed. <h3>Results</h3> A de novo heterozygous c.4031C&gt;T (p.S1344L) variant in the sequence encoding the RNase IIIa domain of <i>DICER1</i> was detected. Clinical investigations revealed a phenotype that resembles the GLOW subphenotype of DICER1 syndrome. <h3>Conclusion</h3> The phenotypic overlap between patients with p.S1344L mutation and GLOW syndrome provide clinical support for recent discoveries that RNase IIIa-Ser1344 site mutations impede miRNA-5p biogenesis analogous to <i>DICER1</i> hotspot mutations in the RNase IIIb domain. We show that an individual with a heterozygous germline p.S1344L mutation has a severe form of DICER1 syndrome (‘DICER1 syndrome plus’), with notable features of intellectual disability, macrocephaly, physical abnormalities, Wilms tumour and a well-differentiated fetal adenocarcinoma of the lung.
Heredity, Health and Personal Beauty.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Liver damage and angiosarcoma in vinyl chloride workers. A systematic detection program
Authors: L. Makk
Journal: JAMA (1974)

Recently, five cases of hepatic angiosarcoma were found in Louisville. All of the patients had worked in a plant engaged in the production of polyvinyl chloride (PVC) from vinyl chloride. A systematic health surveillance program was instituted to detect existing liver damage or angiosarcoma and to find early signs of developing liver damage. A protocol was devised that began with on-site phlebotomies done in the plant and progressed to sophisticated hospital studies, if important abnormalities were found. All of the 1,183 employees of the plant were tested. Two new cases of hepatic angiosarcoma and three cases of portal fibrosis were discovered by this program at the initial screening. It is hoped that continuous health monitoring will aid detection of liver abnormalities while still in a reversible or curable state. (<i>JAMA</i>230:64-68, 1974)
Spontaneous and evoked intracellular calcium transients in donor-derived myocytes following intracardiac myoblast transplantation
Authors: Michael Rubart, Mark H. Soonpaa, Hidehiro Nakajima, Loren J. Field
Journal: Journal of Clinical Investigation (2004)

Skeletal myoblast transplantation is a potential treatment for congestive heart failure. To study the functional activity of both donor and host myocytes following transplantation, skeletal myoblasts expressing an enhanced green fluorescent protein (EGFP) transgene were transplanted into hearts of nontransgenic recipients, and changes in intracellular calcium concentration ([Ca2+]i) were monitored in donor and host cells. While the vast majority of donor-derived myocytes were observed to be functionally isolated from the host myocardium, a small population of donor myocytes exhibited action potential–induced calcium transients in synchrony with adjacent host cardiomyocytes. In many cases, the durations of these [Ca2+]i transients were heterogeneous compared with those in neighboring host cardiomyocytes. In other studies, EGFP-expressing donor myoblasts were transplanted into the hearts of adult transgenic recipient mice expressing a cardiomyocyte-restricted β-gal reporter gene. A small population of myocytes was observed to express both reporter transgenes, indicating that the transplanted myoblasts fused with host cardiomyocytes at a very low frequency. These cells also expressed connexin43, a component of gap junctions. Thus engraftment of skeletal myoblasts generated spatial heterogeneity of [Ca2+]i signaling at the myocardial/skeletal muscle interface, most likely as a consequence of fusion events between donor myoblasts and host cardiomyocytes.
Methoxyflurane Nephropathy
Authors: Richard I. Mazze
Journal: Environmental Health Perspectives (1976)

Investigations of methoxyflurane-induced nephrotoxicity in man have been extensively aided by the use of an animal model. To be of value the animal model must share similar metabolic pathways with man and have the same clinical manifestations of the diseases process. The Fischer 344 rat appears to meet these criteria. The predominant factors in the production of methoxyflurane nephrotoxicity appear to be high methoxyflurane dosage and serum inorganic fluoride concentration. It is likely that secondary factors include: (1) a high rate of methoxyflurane metabolism and sepsitivity of the kidney to inorganic fluoride toxicity: (2) concurrent treatment with other nephrotoxic drugs; (3) preexisting renal disease; (4) surgery of the urogenital tract, aorta, or renal vasculative; (5) repeat administration of methoxyflurane due to accumulation of inorganic fluoride and, perhaps, methoxyflurane induction of its own metabolism: and (6) concurrent treatment with enzyme-inducing drugs such as phenobarbital.
Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma
Authors: R. Amaravadi, L. M. Schuchter, D. F. McDermott, A. Kramer, L. Giles, A. B. Troxel, C. A. Medina, K. L. Nathanson, P. J. O'Dwyer, K. T. Flaherty
Journal: Journal of Clinical Oncology (2007)

8527 Background: The preliminary results for 90 patients (pt) on this 4-arm phase II trial testing sorafenib (SO), an oral Raf kinase/VEGFR2 inhibitor, and temozolomide (TEM) in pt with metastatic melanoma (MM) were presented in 2006. Since then 88% of target accrual is completed and the study is open at a second institution. The primary objective of this study is to estimate the duration of progression- free survival (PFS). Secondary objectives are to determine the optimal dosing of TEM, response, and toxicity rates. Correlative studies include BRAF genotyping and assessment of intratumoral Raf inhibition, and apoptosis. Methods: Pt with MM and ECOG PS&lt;2 are eligible. Prior therapy is allowed. Target accrual is 167 pt in 1 stage. All pt receive SO 400 mg po bid continuously. After 1 week of SO alone, pt without brain metastasis or prior TEM (A+B) are randomized to receive either extended dosing (ED): TEM 75 mg/m 2 po qd for 6/8 weeks (Arm A), or standard dosing (STD): TEM 150 mg/m 2 po qd for days1–5/28 (Arm B). Pt with prior TEM are treated with ED (Arm C) and pt with brain metastasis without prior TEM are treated with STD (Arm D). Responses are assessed using RECIST. Results: Accrual is complete for arms A and B. Results for 147 pt were evaluated ( Table ). SO + TEM resulted in a 19% overall response rate (ORR) [95% CI 11–30%] for pt on arms A+B. In this group, 3/78 pt (4%) developed CNS metastases while on study. Pt on arm D had a 17 % ORR [95% CI 7–34%]. Common grade 3 toxicities were hand-foot syndrome (14%), rash (9%), nausea (9%), and diarrhea (5%). Grade 3 lymphopenia was more common in arm A v. B (43% v. 16%, p=0.01). No significant difference in PFS was found between pt with WT v. mutant BRAF (n=33). Therapy-induced apoptosis was found in 8/9 serial biopsies. Analysis of MAPK phosphorylation in serial biopsies is planned. Conclusions: Updated results confirm the encouraging antitumor activity and tolerability of SO + TEM in pt with MM without a prior history of TEM. No significant financial relationships to disclose. [Table: see text]
LOSS OF LIFE BY FIRE-ARMS.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients
Authors: R. B. Byrd
Journal: JAMA (1979)

One thousand patients receiving isoniazid chemoprophylaxis were prospectively followed up to assess the value of liver function monitoring plus monthly clinical evaluation. Two hundred twenty-two (22.2%) of the patients had at least one elevated SGOT level during the course of treatment, and 47 asymptomatic persons had isoniazid therapy discontinued because of consistent elevations greater than five times normal. Another 17 had symptoms in association with elevated SGOT levels, and therapy was stopped in these patients as well. No patient became seriously ill, and there were no deaths. Biochemical monitoring should be done routinely in patients receiving isoniazid chemoprophylaxis to avoid the development of irreversible hepatic reactions. (<i>JAMA</i>241:1239-1241, 1979)
ALCOHOL AND THE GERM PLASM
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IMPACT OF TOTAL CORONARY CALCIUM SCORE ON PROCEDURAL AND LONG- TERM OUTCOMES IN PATIENTS WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION WITH DRUG ELUTING STENTS: THREE YEARS FOLLOW-UP
Authors: Hae Chang Jeong, Youngkeun Ahn, Doo Sun Sim, Hyun Ju Yoon, Nam Sik Yoon, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang
Journal: Journal of the American College of Cardiology (2010)
Manuscripts Approved for JNCI, June 10 to July 10, 1964
Journal: JNCI Journal of the National Cancer Institute (1964)

Journal Article Manuscripts Approved for JNCI, June 10 to July 10, 1964 Get access JNCI: Journal of the National Cancer Institute, Volume 33, Issue 2, August 1964, Page 372, https://doi.org/10.1093/jnci/33.2.372 Published: 01 August 1964
Vectorcardiographic Notation
Authors: ROBERT A. HELM
Journal: Circulation (1956)

The method of viewing the frontal, sagittal and transverse vectorcardiographic planes is considered from the standpoint of devising a uniform system of measuring angles on these planes. It is pointed out that care must be taken in the selection of oscilloscopic presentations to prevent inconsistency of the signs of the trigonometric functions of such angles. Two groups of oscilloscopic presentations are suggested, either of which permits angles to be measured in a clockwise direction from a reference axis of uniform position on each plane.
Distinct Patterns and Magnitude Of T Cell Responses Are Associated With Seasonal Exposure To Timothy Grass Allergens
Authors: Pearl Bakhru, Carla Oseroff, Veronique M. Schulten, Denise Hinz, Victoria Tripple, Rafeul Alam, David H. Broide, April Frazier, John Sidney, Bjoern Peters, Howard Grey, Alessandro Sette
Journal: Journal of Allergy and Clinical Immunology (2014)
Allergy abstracts
Authors: Murray Albert, N Brooklyn, Eugene Walzer, Harold Friedman, Ohio Monroe, Coleman Stamford, Neil Goldman Ossining, Walzer Brooklyn, N Siegel Broolclyn, N Eloise, Kailin Seguim, Wash Stein, Spring Valley, N Sheldon Berger Freehold
Journal: Journal of Allergy and Clinical Immunology (1976)
CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS
Authors: Walther F. Goebel
Journal: The Journal of Experimental Medicine (1936)

1. Artificial carbohydrate-protein antigens containing the azobenzylglycosides of glucose and glucuronic acid give rise in rabbits to antibodies which are distinct and immunologically specific. 2. The artificial antigen containing glucuronic acid reacts in high dilutions in antipneumococcus horse sera Types II, III, and VIII. The chemical basis for this serological activity is discussed.
Azithromycin for Prevention of Exacerbations of COPD
Authors: Seth Seabury, Santa Monica, Amitabh Chandra, Darius Lakdawalla, Anupam Jena
Journal: New England Journal of Medicine (2012)

all specialties, but there was still significant variation (from $7,283 in nephrology to $25,073 in gynecology).The correlation between mean costs in claims with and without payments was small and positive (0.39).These findings show that although the costs of dispute resolution are higher for claims that result in indemnity payments, there is still a meaningful cost of resolving claims that never result in payment.Moreover, there is substantial variation in these costs across specialties, though this variation is not necessarily the same as the variation in the frequency or size of claims.Lowering the costs of dispute resolution could lead to considerable savings for physicians and insurers, particularly in specialties with high mean defense costs.